NCT03076372: A Study Evaluating MM-310 in Patients With Solid Tumors

NCT03076372
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT03076372

Comments are closed.

Up ↑